D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects

被引:20
作者
Broich, K
Grunwald, F
Kasper, S
Klemm, E
Biersack, HJ
Moller, HJ
机构
[1] Univ Halle Wittenberg, Psychiat Klin & Poliklin, D-06097 Halle, Germany
[2] Univ Bonn, Inst Klin & Expt Nukl Med, D-5300 Bonn, Germany
[3] Univ Vienna, Abt Allgemeine Psychiat, A-1010 Vienna, Austria
[4] Univ Munich, Psychiat Klin, D-80539 Munich, Germany
关键词
D O I
10.1055/s-2007-979321
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to compare striatal D-2 dopamine receptor occupancy of various typical neuroleptics and clozapine in relation to the occurrence of extrapyramidal side effects (EPS). Forty-four inpatients with schizophrenia, including 12 patients with schizodominant schizoaffective disorder, were evaluated using I-123-iodobenzamide (IBZM) and single photon emission computed tomography. Striatal D-2 dopamine receptor occupancy was estimated by use of a striatal/frontal cortex ratio (ST/FC) of IBZM binding. Fourteen patients were neuroleptic-free and served as controls. Six patients were treated with clozapine and 24 patients were treated with various typical neuroleptics. ST/FC ratios in patients taking typical neuroleptics were significantly lower than those who were neuroleptic free or treated with clozapine. Patients with EPS had lower ST/FC ratios than those without EPS. A significant linear relationship between ST/FC ratios and severity of EPS estimated by the Simpson-Angus-Scale was established (r=-0.51, p=0.041).
引用
收藏
页码:159 / 162
页数:4
相关论文
共 26 条
[1]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[2]   STRIATAL DOPAMINE RECEPTOR OCCUPANCY DURING AND FOLLOWING WITHDRAWAL FROM NEUROLEPTIC TREATMENT - CORRELATIVE EVALUATION BY POSITRON EMISSION TOMOGRAPHY AND PLASMA PROLACTIN LEVELS [J].
BARON, JC ;
MARTINOT, JL ;
CAMBON, H ;
BOULENGER, JP ;
POIRIER, MF ;
CAILLARD, V ;
BLIN, J ;
HURET, JD ;
LOCH, C ;
MAZIERE, B .
PSYCHOPHARMACOLOGY, 1989, 99 (04) :463-472
[3]  
BROICH K, 1992, Journal of Nuclear Medicine, V33, P898
[4]  
BRUCKE T, 1993, ADV NEUROL, V60, P494
[5]   STRIATAL DOPAMINE D2-RECEPTOR BLOCKADE BY TYPICAL AND ATYPICAL NEUROLEPTICS [J].
BRUCKE, T ;
ROTH, J ;
PODREKA, I ;
STROBL, R ;
WENGER, S ;
ASENBAUM, S .
LANCET, 1992, 339 (8791) :497-497
[6]  
BRUCKE T, 1991, J CEREBR BLOOD F MET, V11, P220
[7]   DOPAMINE D-2 RECEPTOR BLOCKADE IN-VIVO WITH THE NOVEL ANTIPSYCHOTICS RISPERIDONE AND REMOXIPRIDE - AN I-123 IBZM SINGLE-PHOTON EMISSION TOMOGRAPHY (SPET) STUDY [J].
BUSATTO, GF ;
PILOWSKY, LS ;
COSTA, DC ;
ELL, PJ ;
VERHOEFF, NPLG ;
KERWIN, RW .
PSYCHOPHARMACOLOGY, 1995, 117 (01) :55-61
[8]   INVIVO ASSAY FOR NEUROLEPTIC RECEPTOR-BINDING IN THE STRIATUM - POSITRON TOMOGRAPHY IN HUMANS [J].
CAMBON, H ;
BARON, JC ;
BOULENGER, JP ;
LOCH, C ;
ZARIFIAN, E ;
MAZIERE, B .
BRITISH JOURNAL OF PSYCHIATRY, 1987, 151 :824-830
[9]   IN VIVO CHARACTERISATION OF 3-IODO-6-METHOXYBENZAMIDE I-123 IN HUMANS [J].
COSTA, DC ;
VERHOEFF, NPLG ;
CULLUM, ID ;
ELL, PJ ;
SYED, GMS ;
BARRETT, J ;
PALAZIDOU, E ;
TOONE, B ;
VANROYEN, E ;
BOBELDIJK, M .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1990, 16 (11) :813-816
[10]  
FARDE L, 1992, ARZNEIMITTEL-FORSCH, V42-1, P260